We found that i.t. injection of a combination of VV-GMCSF and VV-neu, but not VV-GMCSF alone, induced a systemic anti-neu CD8+ T-cell response (Figure 3a), led to tumor regression (Figure 3b), and decreased splenic and TME MDSC population (Figure 3c) [91,92]. This evidence concerns the gene ERBB2 and neoplasm.